pharmaceuticals

Correction

Correction: Vassallo et al. Hyaluronic Acid-Based Injective Medical Devices: In Vitro Characterization of Novel Formulations Containing Biofermentative Unsulfated Chondroitin or Extractive Sulfated One with Cyclodextrins. *Pharmaceuticals* 2023, *16*, 1429

Valentina Vassallo [1], Celeste Di Meo [1], Giuseppe Toro [2], Alberto Alfano [1], Giovanni Iolascon [2] and Chiara Schiraldi [1,*]

[1] Department of Experimental Medicine, Section of Biotechnology, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy; valentina.vassallo@unicampania.it (V.V.); celeste.dimeo@unicampania.it (C.D.M.); alberto.alfano@unicampania.it (A.A.)
[2] Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy; giuseppe.toro@unicampania.it (G.T.); giovanni.iolascon@unicampania.it (G.I.)
* Correspondence: chiara.schiraldi@unicampania.it; Tel.: +39-0815667546

In the original publication [1], there were mistakes in Figure 1 caption and the location of some software companies.

1. Error in Figure 1 Caption

Chondroitin sulfated should be **chondroitin sulfate**.

The corrected **"Figure 1 caption"** appears below.

Figure 1. Mechanical spectra of the preparations as commercialized. HHA + CS + cd: hyaluronic acid sodium salt 2% (*w*/*v*), marine chondroitin sulfate 2% (*w*/*v*), and cyclodextrins 1% (*w*/*v*); HHA/BC: hyaluronic acid sodium salt 2.4% (*w*/*v*) and unsulfated chondroitin 1.6% (*w*/*v*).

2. Errors in Software Company Locations

IBSA Farmaceutici (Lodi, CA, USA) should be **IBSA Farmaceutici, Lodi, Italy;** Kolinpharma (Lodi, CA, USA) (Kolinpharma) should be **Kolinpharma, Milan, Italy;** BD Falcon (BD, Falcon, USA) should be **BD, Falcon, Franklin Lakes, NJ, USA;** Company (Beckman, Milano, Italy) should be **Beckman, Milan, Italy;** Bio-Rad (Bio-Rad, Milan, Laboratories) should be **Bio-Rad Laboratories, Milan, Italy;** Thermo Fisher Scientific (ThermoFisher Scientific, USA) should be **Thermo Fisher Scientific, Waltham, MA, USA.**

The corrected contents appears below.

Paragraphs 1 and 2 of Section 4.1. ***Class III Medical Device Based on HA and CS or BC***:

Sinogel® 3 mL (IBSA Farmaceutici, Lodi, Italy) (here referred to as HHA/BC) was kindly provided by IBSA Farmaceutici Italia.

Dolatrox® (Kolinpharma, Milan, Italy) (here referred to as HHA + CS + cd) was bought in a pharmacy; it is reported to contain hyaluronic acid sodium salt 2% (*w*/*v*), chondroitin sulfate 2% (*w*/*v*), and cyclodextrins 1% (*w*/*v*).

Paragraphs 1 of Section 4.4. ***OA In Vitro Model Setup***:

The next day, the cell suspension was filtered (70 µm, BD Falcon, Franklin Lakes, NJ, USA), centrifuged at 1500 rpm for 7 min (Eppendorf Centrifuge), washed with PBS, and re-centrifuged.

Paragraphs 1 of Section 4.5. ***Cellular Viability Assay***:

check for updates

Citation: Vassallo, V.; Di Meo, C.; Toro, G.; Alfano, A.; Iolascon, G.; Schiraldi, C. Correction: Vassallo et al. Hyaluronic Acid-Based Injective Medical Devices: In Vitro Characterization of Novel Formulations Containing Biofermentative Unsulfated Chondroitin or Extractive Sulfated One with Cyclodextrins. *Pharmaceuticals* 2023, *16*, 1429. *Pharmaceuticals* **2023**, *16*, 1685. https://doi.org/10.3390/ph16121685

Received: 22 November 2023
Accepted: 22 November 2023
Published: 4 December 2023

The optical densities of the supernatants were measured at 450 nm using a Beckman DU 640 spectrometer (Beckman, Milan, Italy) after specific treatments and incubation with a cell counting solution.

Paragraphs 1 of Section 4.6. ***Gene Expression Analyses via qRT-PCR***:

The variation of gene expression was calculated by normalizing the data about GAGs treated cells with respect to pCTRL, applying the Livak method ($2^{-\Delta\Delta Ct}$) [55] and using Bio-Rad iQ™5 Optical System Software, Version 2.1 (Bio-Rad Laboratories, Milan, Italy).

Paragraphs 1 of Section 4.7. ***Protein Analyses via Western Blotting***:

Primary chondrocytes were seeded in a 12-well standard plate (BD Falcon, Franklin Lakes, NJ, USA) (30×10^3 cells/well) and in vitro cultivated in the presence or not (pCTRL) of GAGs-based gels for 7 days at a final concentration in the culture medium of 4 mg/mL.

Paragraphs 1 of Section 4.8. ***Immunofluorescence Analyses***:

To analyze the protein expression of COLII via immunofluorescence staining (IF), primary chondrocytes were seeded in a chamber slide (BD Falcon, Franklin Lakes, NJ, USA) (5×10^3 cells/well) and in vitro cultivated in the presence or not (pCTRL) of GAG-based medical devices (4 mg/mL) for 24 h.

Then, the slices were incubated with a FITC-conjugated goat anti-rabbit secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA) (diluted 1:200) for 1 h at room temperature and covered using the mounting medium with DAPI-aqueous.

Paragraphs 1 of Section 4.9. ***ELISA Assay***:

Each experiment was performed in triplicate, and the cytokine was quantified by a microplate reader (Bio-Rad Laboratories, Milan, Italy).

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. Vassallo, V.; Di Meo, C.; Toro, G.; Alfano, A.; Iolascon, G.; Schiraldi, C. Hyaluronic Acid-Based Injective Medical Devices: In Vitro Characterization of Novel Formulations Containing Biofermentative Unsulfated Chondroitin or Extractive Sulfated One with Cyclodextrins. *Pharmaceuticals* **2023**, *16*, 1429. [CrossRef] [PubMed]